This handout is for refractory atrial flutter — cardioversion-failed. Your care team identified this based on: persistent atrial flutter despite ≥2 dccv attempts at max 200 j biphasic energy — refractory phenotype.
Other reasons your team may use this plan: failed chemical cv with ibutilide and amiodarone load — definitive aad failure; long-standing persistent flutter >1 year + structural la remodeling — fixed substrate, low cv success expected.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| metoprolol_succinate | 50–100 mg PO daily titrate to HR 80–110 | PO | once daily | Long-acting BB for refractory rate control bridge to ablation — ACC/AHA 2024 (PMID 38753446) |
| diltiazem | 120–360 mg PO daily; IV 0.25 mg/kg bolus → 5–15 mg/h infusion if breakthrough RVR | IV/PO | daily PO; bolus + infusion if breakthrough | AVN slowing alternative; AVOID in HFrEF EF<40 — ACC/AHA 2024 (PMID 38753446) |
| amiodarone | 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance | IV/PO | load + daily | Bridge AAD to ablation in refractory cases; pulm/thyroid/LFT monitoring — ACC/AHA 2024 (PMID 38753446) |
| dofetilide | 125–500 mcg PO BID per CrCl (REMS — inpatient initiation × 3 d) | PO | BID | Alternative class III; dofetilide REMS — inpatient initiation with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446) |
| sotalol | 80–160 mg PO BID inpatient initiation per CrCl + QTc | PO | BID | Class III with BB activity; QT prolongation risk — ACC/AHA 2024 |
| apixaban | 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) | PO | BID | Lifelong AC; therapeutic ≥3 wk pre-ablation OR TEE-guided strategy — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978) |
| rivaroxaban | 20 mg with food (15 mg if CrCl 15–50) | PO | once daily | X-VeRT (PMID 24837375) — peri-CV efficacy = warfarin |
| warfarin | 5 mg daily; INR target 2–3 | PO | daily | Mechanical valve / severe MS / DOAC-ineligible — ACC/AHA 2024 (PMID 38753446) |
| cti_catheter_ablation | Single linear ablation lesion at cavotricuspid isthmus | procedural | one-time | >95% acute success for typical flutter — Calkins 2007 (PMID 17572388); ACC/AHA 2024 Class I |
| avn_ablation_with_permanent_pacemaker | Junctional ablation + pre-implanted permanent pacemaker (typically biventricular if EF reduced) | procedural | one-time | Last-line for refractory RVR — creates pacer-dependence; ACC/AHA 2024 IIa (PMID 38753446) |
Plan: Refractory atrial flutter — ablation-first pathway (CTI for typical, 3D mapping for atypical, AVN ablation + pacemaker for ablation-contraindicated symptomatic) + lifelong AC + lifestyle modification — ACC/AHA 2024 (Joglar PMID 38753446); LEGACY (Pathak PMID 25770315)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
EP at 4 weeks post-ablation; cardiology q3–6 mo; AC continuation lifelong; Holter at 3, 6, 12 mo for recurrence; lifestyle (alcohol, weight, OSA); pacer clinic q6m if AVN ablation; surveillance for atrioesophageal fistula warning weeks 2–6 post-LA ablation
Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); ESC 2024 AF (Van Gelder PMID 39050851); HRS/EHRA/ECAS 2007 catheter ablation expert consensus (Calkins PMID 17572388)